SINCO PHARMA released its annual performance, with a profit attributable to shareholders of HKD 42.045 million, a year-on-year decrease of 0.7%
SINCO PHARMA released its annual results for the year ending December 31, 2024, with revenue of 2.821 billion yuan, a year-on-year increase of 11.07%. The profit attributable to shareholders was 42.045 million yuan, a year-on-year decrease of 0.7%. Earnings per share were 0.02 yuan, and a final dividend of 0.20 Hong Kong cents is proposed. Gross profit decreased to 299.9 million yuan, with a gross profit margin falling to 10.6%, mainly due to increased procurement costs caused by the depreciation of the US dollar
According to the Zhitong Finance APP, SINCO PHARMA (06833) announced its annual performance for the year ending December 31, 2024. The group achieved revenue of RMB 2.821 billion (same unit below), an increase of 11.07% year-on-year; the profit attributable to the company's owners was RMB 42.045 million, a decrease of 0.7% year-on-year; earnings per share were RMB 0.02, and a final dividend of HKD 0.20 per ordinary share is proposed.
During the reporting period, the group's gross profit decreased by RMB 23.4 million to RMB 299.9 million (2023: RMB 323 million), and the gross profit margin fell from 12.7% in 2023 to 10.6% during the reporting period. The decrease in gross profit was mainly due to the further depreciation of the RMB against the USD, leading to increased procurement costs, with the sales cost of human albumin rising more than the increase in sales revenue
